The FDA cleared an investigational new drug application for ATA2271, a chimeric antigen receptor T-cell therapy [ or CAR T-cell therapy ] for the treatment of advanced mesothelioma, according to the agent’s manufacturer [which is working together with Memorial Sloan Kettering Cancer Center].
ATA2271 (Atara Biotherapeutics) is an autologous CAR T-cell therapy that targets the mesothelin antigen expressed on the surface of certain solid tumors.
The investigational [ CAR T-cell therapy ] agent — being developed as part of a collaboration with Memorial Sloan Kettering Cancer Center — combines two novel proprietary technologies, according to Atara.
The first is a 1XX costimulatory domain technology to simultaneously extend T-cell effector function while limiting cell exhaustion. This technology was developed by the lab of Michel Sadelain, MD, PhD, director of the Center for Cell Engineering at Memorial Sloan Kettering.
The second is a genetic modification to the CAR T cells to achieve checkpoint blockade by PD-1 DNR that overcomes the immune suppression of PD-L1. The technology was developed in collaboration with Prasad S. Adusumilli, MD, FACS, a thoracic surgeon who specializes in solid tumor cellular therapies and codirector of the mesothelioma program at Memorial Sloan Kettering.
[Article continues at original source]
Asbestos & Mesothelioma Information
Asbestos-Mesothelioma Case Evaluation
Free. Confidential. No Obligation.